Heart Failure Mechanisms and Management Strategies

Heart failure arises when the heart is unable to pump sufficient blood to meet the body’s metabolic demands. It is broadly classified by left ventricular ejection fraction into reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF) phenotypes. In HFrEF, loss of contractile function and maladaptive remodelling predominate, whereas HFpEF is driven by diastolic dysfunction, increased myocardial stiffness, systemic inflammation and microvascular impairment. Central mechanisms include neurohormonal activation of the renin–angiotensin–aldosterone and adrenergic systems, adverse extracellular matrix remodelling, titin phosphorylation defects and endothelial–cardiomyocyte crosstalk. Comorbidities such as diabetes, hypertension and obesity exacerbate myocardial fibrosis, chronic low-grade inflammation and impaired coronary microcirculation. Management strategies have evolved from conventional diuretics, β-blockers and renin–angiotensin inhibitors towards sodium–glucose cotransporter 2 inhibitors, neprilysin antagonists and tailored device therapies. In HFpEF, the heterogeneity of underlying mechanisms has stimulated precision medicine approaches, combining pharmacological modulation of cGMP–PKG signalling, anti-fibrotic agents and phenotype-directed interventions. Globally, these advances have translated into reduced hospital admissions, improved functional capacity and attenuation of disease progression.

Research from Nature Portfolio

Recent studies have introduced hierarchical composite analyses to capture both cardiovascular and renal benefits of therapies, using win statistics to integrate mortality, kidney function decline and hospital admissions into a single evaluative framework. A patient-level pooled analysis of sodium–glucose cotransporter 2 inhibition demonstrated consistent reductions in cardiovascular death, all-cause mortality and heart failure hospitalisations across the full spectrum of ejection fraction. Transcriptomic profiling of ventricular biopsies has identified distinct gene-expression signatures in patients with preserved ejection fraction, revealing alterations in oxidative phosphorylation, matrix organisation and upstream transcriptional regulators. These findings underscore the value of advanced analytics and molecular phenotyping in elucidating disease pathways and refining therapeutic targets.

Heart Failure Mechanisms and Management Strategies publication trend

The graph below shows the total number of articles in heart failure mechanisms and management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Ejection fraction (EF): Percentage of blood ejected from the left ventricle with each contraction, used to classify heart failure phenotypes.

SGLT2 inhibitor: Agent that blocks renal sodium–glucose cotransporter 2, lowering glucose reabsorption and conferring cardiovascular protection.

Extracellular matrix (ECM): Network of proteins and polysaccharides that provide structural support and modulate myocardial stiffness.

Titin: Giant elastic filament in cardiomyocytes that determines passive stiffness and contributes to diastolic function.

Microvascular dysfunction: Impairment of small vessel function leading to inadequate tissue perfusion, inflammation and remodelling.

References

1. A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. Nature Medicine (2024).
2. Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells (2020).
3. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine (2022).
4. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology (2020).
5. Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Research in Cardiology (2020).
6. Transcriptomics of cardiac biopsies reveals differences in patients with or without diagnostic parameters for heart failure with preserved ejection fraction. Scientific Reports (2019).